HF
BFRI icon

HRT Financial’s Biofrontera BFRI Stock Holding History

HRT Financial’s Portfolio BFRI Stock Details BFRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,086
Closed -$8K – 2870
2025
Q2 		$8K Buy
+12,086
New +$8.45K ﹤0.01% 2462
2024
Q2 		– Sell
-10,639
Closed -$16K – 2230
2024
Q1 		$16K Buy
+10,639
New +$14.7K ﹤0.01% 2026

Other funds holding BFRI

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial's BFRI Position: Q3 2025 in Review

HRT Financial sold out of Biofrontera (BFRI) in Q3 2025, closing a stake of 12,086 shares — an estimated $8K sold.

HRT Financial first reported a position in BFRI in Q1 2024 and held it in 2 quarters. The position peaked at $16K in Q1 2024. 13 funds tracked by Wall St. Rank hold BFRI as of Q3 2025.

  • HRT Financial reported no remaining Biofrontera position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 12,086 Biofrontera shares in Q3 2025, an estimated $8K.
  • HRT Financial first reported a position in Biofrontera in Q1 2024 and held it in 2 quarters.
  • HRT Financial's Biofrontera position peaked at $16K in Q1 2024.
  • 13 funds tracked by Wall St. Rank held Biofrontera as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.